Abdelfatah Mohamed M, Elhanafi Sherif, Zuckerman Marc J, Othman Mohamed O
a Division of Gastroenterology, Department of Internal Medicine , East Carolina University , Greenville , NC , USA.
b Gastroenterology and Hepatology Section , University of Pennsylvania , Philadelphia , PA , USA.
Scand J Gastroenterol. 2017 Oct;52(10):1148-1157. doi: 10.1080/00365521.2017.1339827. Epub 2017 Jun 23.
Adenoma detection rate (ADR) is the most validated quality indicator for colonoscopy. Calculating ADR may not yield information in regards to advanced adenoma detection rate (advanced ADR). In addition, calculating ADR for individual endoscopists cannot distinguish between those who find only one versus more than one adenoma per colonoscopy. Several novel quality indictors were recently proposed to ensure adequate assessment of quality during colonoscopy. Our study aims to determine the correlation between ADR and novel quality indicators.
A retrospective cohort study of patients undergoing screening colonoscopy in a university hospital setting. Patient characteristics and colonoscopy findings were combined and analyzed to calculate the correlation of ADR with novel quality indicators using Spearman's rank-order correlation were used.
A total of 1433 patients out of 2116 patients met the inclusion criteria. There was a significant positive correlation between ADR correlated with [advanced-ADR-2, nonadvanced-ADR, adenoma per colonoscopy, Multiplicity detection rate and ADR-Plus] r = (0.82, 0.99, 0.99, 0.07 and 0.85), respectively. However, ADR did not correlate with advanced-ADR and adenomas per positive participant.
Adding advanced-ADR and adenomas per positive participant to ADR may create a more comprehensive quality indicators tool kit, which is sensitive and difficult to game. Future studies are needed to investigate the impact of the tool kit on the interval cancers and adenoma missing rate.
腺瘤检出率(ADR)是结肠镜检查中最有效的质量指标。计算ADR可能无法提供有关高级别腺瘤检出率(进展期ADR)的信息。此外,计算个体内镜医师的ADR无法区分每次结肠镜检查仅发现一个腺瘤与发现多个腺瘤的医师。最近提出了几种新的质量指标,以确保在结肠镜检查期间对质量进行充分评估。我们的研究旨在确定ADR与新质量指标之间的相关性。
对在大学医院接受筛查结肠镜检查的患者进行回顾性队列研究。结合并分析患者特征和结肠镜检查结果,使用Spearman等级相关分析来计算ADR与新质量指标之间的相关性。
2116例患者中有1433例符合纳入标准。ADR与[进展期ADR-2、非进展期ADR、每次结肠镜检查腺瘤数、多重性检出率和ADR加]之间存在显著正相关,r分别为(0.82、0.99、0.99、0.07和0.85)。然而,ADR与进展期ADR和每个阳性参与者的腺瘤数无相关性。
在ADR中加入进展期ADR和每个阳性参与者的腺瘤数可能会创建一个更全面的质量指标工具包,该工具包敏感且难以被操纵。未来需要进行研究以调查该工具包对间期癌和腺瘤漏诊率的影响